Industry Supported Sessions

​​​​​​​​​​​​​​​​​

Tuesday​, 10 May 2016​​

​Time​Hall B​Hall C​Hall D​Hall EHall ​F
​12:30-14:00​​Bayer ​​Medtronic​Penumbra​Boehringer Ingelheim​Amgen​
18:00-19:30​Takeda​Stryker​EVER Neuro Pharma​


​Wednesday, 11 May 2016

​​TimeHall A​Hall B​Hall C​Hall D​Hall E​Hall F
​12:45-14:15​Astra Zeneca

EBAC Accredited Educational Programme

(For more details, please click here)​

​Bayer​Medt​ronicBMS & Pfizer Alliance​​Boehringer Ingelheim​Daiichi-Sankyo​


​​Thursday, 12 May 2016

​​​TimeHall F
13:15 - 14:15​St Jude Medical


Tuesday​, 10 May 2016​​


PREVENTION AND MANAGEMENT OF STROKES WITH NOACS: HOW BOTH STUDY AND REAL-WORLD EXPERIENCE INFORM CURRENT PRACTICE

Tuesday, 10 May 2016
12:30 - 14:00, Hall B

Symposium is organised and supported by Bayer
Chairs: Pierre Amarenco (France) and Graeme Hankey (Australia)

12:3​0 - 12:55

CLINICAL TRIAL AND REAL-WORLD EVIDENCE: A BROAD PERSPECTIVE FROM THE LITERATURE
Graeme Hankey (Australia)

12:55 - 13:10

REAL-WORLD FINDINGS FROM THE XANTUS STUDY
Pierre Amarenco (France)

13:10 - 13:40PRACTICAL CONSIDERATIONS FOR STROKE PHYSICIANS: A CASE-BASED INTERDISCIPLINARY DEBATE
Sven Poli (Germany)
Jan Beyer-Westendorf (Germany)
13:40 - 13:50

Q&A AND PANEL DISCUSSION

13:50 - 14:00

CONCLUSION AND CLOSE: FUTURE PERSPECTIVES FOR RIVAROXABAN FOR STROKE PREVENTION
Pierre Amarenco (France)​

__________________________________________________________________


AIS TREATMENT: FROM CLINICAL EVIDENCE TO PRACTICE!

Tuesday, 10 May 2016
12:30 - 14:00, Hall C

Symposium is organised and supported by Medtronic
Chair: Mayank Goyal (Canada)

12:30 - 12​:55

NEUROLOGIST, FROM PAST TO FUTURE
Patrik Michel (Switzerland)

12:55 - 13:20

ENDOVASCULAR TREATMENT OF ISCHEMIC STROKE
Christophe Cognard (France)

13:20 - 13:45

COST EFFECTIVENESS OF SOLITAIRE™  ​
Kyriakos Lobotesis (United Kingdom) 

13:45 -​ 14:00

Q&A​ 

__________________________________________________________________

TECHNOLOGY ADVANCES IN ISCHEMIC AND HEMORRHAGIC STROKE TREATMENT: A CLINICAL UPDATE

Tuesday, 10 May 2016
12:30 - 14:00, Hall D

Symposium is organised and supported by Penumbra
Chair: David Fiorella (USA)  

12:30 - 13:00

RACER: RESULTS OF THE ACE64 EUROPEAN MULTI-CENTER EXPERIENCE
Annika Kowoll (Germany) 

13:00 - 13:30

A COMPARISON OF CLINICAL OUTCOMES WITH ADAPT AND SOLUMBRA
Mark L. Young (USA)​​​​ ​

​13:30 - 14:00CHARTING A COURSE FOR ICH - EARLY EXPERIENCE WITH THE APOLLO SYSTEM 
David Fiorella (USA)  

​__________________________________________________________________​

ADVANCING ANTICOAGULATION CARE: THE FIRST NOAC WITH A SPECIFIC REVERSAL AGENT

Tuesday, 10 May 2016
12:30 - 14:00, Hall E​

Symposium is organised and supported by Boehring​er Ingelheim

Chairs: Valeria Caso (Italy) and Hans-Christoph Diener (Germany)​

12:30 - 12:35WELC​OME
Valeria Caso (Italy)
12:35 - 12:50ANTICOAGULATION 1.0 TO 2.0: THE NOAC REVOLUTION STARTED WITH DABIGATRAN
Hans-Christoph Diener (Germany)
12:50 - 12:55AUDIENCE Q&A
Valeria Caso (Italy)
12:55 - 13:15ANTICOAGULATION 3.0: INTROD​UCING IDARUCIZUMAB
Richard Bernstein (USA)
13:15 - 13:45INTERACTIVE CASES: ANTICOAGULATION REVERSAL IN YOUR CLINIC
Marting Grond (Germany) & Ken Butcher (Canada)
13:45 - 14:00PANEL DISCUSSION AND AUDIENCE Q&A
Valeria Caso (Italy) & Hans-Christoph Diener (Germany)​

Prescribing information is available from the booth. In Spain, idarucizumab is pending for price and reimbursement.
__________________________________________________________________

PCSK9 INHIBITION: A NEW APPROACH TO MANAGING RESIDUAL CV RISK


Tuesday, 10 May 2016
12:30 - 14:00, Hall F

Symposium is organised and supported by Amgen

Chair: Matthias Endres (Germany) and Ulrich Laufs (Germany)​

12:30 - 12:3​​5

WELCOME AND INTRODUCTIONS
Matthias Endres (Germany)

12:35 - 13:00

STROKE AND CHOLESTEROL
Matthias Endres (Germany)

13:00 - 13:25

PCSK9 INHIBITORS AND THEIR BENEFICIAL EFFECTS ON LIPID PROFILE
Ulrich Laufs (Germany)

13:25 - 1​3:45

WILL LOWERING LDL-C WITH PCSK9 INHIBITORS REDUCE CV RISK?

Neil Poulter (United Kingdom)

​1​3:45​ - 13:55PANEL DISCUSSION

13:55 - 14:00

 CLOSING REMARKS
Matthias Endres (Germany) and​​ Ulrich Laufs (Germany)

__________________________________________________________________

MULTIMODAL APPROACH IN THE TREATMENT IN POST-STROKE COGNITIVE IMPAIRMENT (PSCI)​

Tuesday, 10 May 2016
18:00 - 19:30, Hall B

Symposium is organised and supported by Takeda

Chair: Alla Guekht (Russia)

18:00 - 18:10

WELCOME/INTRODUCTION
Alla Guekht (Russia) 

18:10 - 18:30

POST-STROKE NEUROREPAIR AND COGNITIVE REHABILITATION               

Jerzy Krupinski (Spain) 

18:30 - 18:50

PHARMACOLOGICAL TREATMENT OPTIONS OF PSCI

Eduard  Yakupov (Russia) 

18:50 - 19:15

EVOLVING THE CONCEPT OF POST-STROKE COGNITIVE IMPAIRMENT: ARTEMIDA RESULTS​

Alla Guekht (Russia) 

19:15 - 19:30

DISCUSSION​ 

​__________________________________________________________________

HOW PATIENT PATHWAY SYSTEMS, TREATMENT TIMES AND REGIONAL DEMOGRAPHICS IMPACT PATIENT OUTCOMES
 ​

Tuesday, 10 May 2016
18:00 - 19:30, Hall C

Symposium is organised and supported by Stryker ​

​Chairs: Atte Meretoja (Finland)    

18​:00 - 18:20

OPTIMIZATION OF IN-HOSPITAL PATIENT PATHWAYS FOR THROMBOLYSIS AND LEARNINGS FOR MECHANICAL THROMBECTOMY            
Atte Meretoja (Finland)                

18:20 - 18:40

EXTENDING THE TIME-WINDOW: DAWN™ TRIAL UPDATE
Marc Ribó (Spain)

18:40 - 19:00

TREVO® RETRIEVER REGISTRY: A GLOBAL COMPARATIVE ANALYSIS OF 500 PATIENTS
Antonin Krajina (Czech Republic) 

19:00 - 19:30

DEBATE ​

__________________________________________________________________

ADVANCES IN SUB-ACUTE STROKE MOTOR RECOVERY

Tuesday, 10 May 2016
18:00 - 19:30, Hall D

Symposium is organised and supported by​ EVER Neuro Pharma 

Chair: Valeria Caso (Italy)

18:00 - 18:20

STROKE RECOVERY:  TIMING, TRAINING, & BIOLOGICAL DETERMINANTS
Steven Zeiler (

USA) 

8:40

MOTOR RECOVERY AFTER STROKE – CHALLENGES & OPPORTUNITIES
Andreas Winkler (Austria) 

18:40 - 19:00

MODULATION OF NEURAL PLASTICITY AND RECOVERY AFTER STROKE: NONINVASIVE BRAIN STIMULATION AND REHABILITATION
Yun Hee Kim (Korea)

19:00 - 19:20

PHARMACOLOGICAL AND EARLY REHABILITATION TREATMENT – THE CARS-TRIAL RESULTS
Dafin Muresanu (Romania) 

19:20 - 19:30Q & A​​

​Wednesday, 11 May 2016


STROKE PREVENTION IN AF: A YEAR 2016 UPDATE FOR THE NEUROLOGY AND STROKE SPECIALIST
FOCUS ON THE ROLE OF FACTOR XA INHIBITION FOR PREVENTION OF THROMBOEMBOLIC STROKE IN AF: PRINCIPLES OF PRACTICE AT THE FRONT LINES OF STROKE AND NEUROVASCULAR CARE​

Wednesday, 11 May 2016
12:45 - 14:15, Hall B​

Symposium is organised and supported by Bayer

Chair: Hans-Christoph Diener (Germany)

12:45 - 12:50

 

PROGRAM CHAIRMAN'S INTRODUCTION AND WELCOME
Hans-Christoph Diener (Germany) 

12:50 - 13:05

 

THE BURDEN OF THROMBOEMBOLIC STROKE IN THE GENERAL AND AGING POPULATION: FOCUS ON STROKE PREVENTION AND MANAGEMENT FOR THE NEUROVASCULAR AND STROKE SPECIALIST

Pierre Amarenco (France) 

13:05 - 13:25

 

ASE

John Camm (United Kingdom) 

13:25 - 13:45

 

THE USE OF ORAL FACTOR XA INHIBITORS IN THE SETTING OF ACUTE THROMBOEMBOLIC STROKE IN PATIENTS WITH NVAF: PRACTICAL STRATEGIES FOR INITIATING ANTICOAGULATION IN AF PATIENTS WITH RECENT TIA OR STROKE: WHEN? IN RELATION TO THROMBOLYSIS? AT WHAT DOSE? WHICH AGENT OPTIMIZES THE BENEFIT-TO-RISK RATIO?

Peter Verhamme (Belgium) 

13:45

- 14:00

 

INTERACTIVE CASE-BASED SIMULATION FOCUSED ON STROKE PREVENTION IN THE HIGH RISK PATIENT WITH AF: PRACTICAL, REAL WORLD MANAGEMENT DECISIONS FOR THE NEUROLOGIST AND STROKE SPECIALISTS USING ORAL FACTOR XA INHIBITORS IN PATIENT WITH AF AT RISK FOR STROKE: WHAT DOSE? WHY? WHICH PATIENTS? ASSESSING TREATMENT RESULTS

Programme Chair and Distinguished Faculty 

14:00 - 14:10

 

SUMMARY AND TAKE HOME MESSAGES: THE FOUNDATION ROLE OF ORAL FACTOR XA INHIBITION FOR STROKE PREVENTION IN AF: WHAT HAVE LANDMARK TRIALS AND REAL WORLD EXPERIENCE TAUGHT US?

Hans-Christoph Diener (Germany) 

14:10 - 14:15

INTERACTIVE QUESTION AND ANSWER SESSION
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Massachusetts Medical School Office of Continuing Medical Education (UMMS-OCME) and CMEducation Resources, LLC. The UMMS-OCME is accredited by the ACCME to provide continuing medical education for physicians.

The University of Massachusetts Medical School designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

__________________________________________________________________


FROM PROPHYLAXIS OF VTE TO UNCOVERING ATRIAL FIBRILLATION IN CRYPTOGENIC STROKE PATIENTS

Wednesday, 11 May 2016​
12:45 - 14:15, Hall C

Symposium is organised and supported by Medtronic

Chair: Martin Grond (Germany) and Stefano Ricci (Italy)

12:45 - 12:50

EN
​​Martin Grond (Germany) and Stefano Ricci (Italy) 

12:50 - 13:10

FROM CLOTS3 OUTCOMES TO NEWEST RECOMMENDATIONS ON THE PROPHYLAXIS OF VTE IN STROKE PATIENT
Carlos Molina (Spain) 

13:10 - 13:30

THE IMPLEMENTATION OF A PRACTICAL PROTOCOL FOR THE PROPHYLAXIS OF VTE IN STROKE PATIENTS
Carol Williams (United Kingdom)

13:30 - 13:50

UNCOVERING ATRIAL FIBRILLATION BEYOND SHORT-TERM MONITORING IN CRYPTOGENIC STROKE PATIENTS
Johannes Brachmann (Germany) 

13:50 - 14:10

IS MONITORING FOR ATRIAL FIBRILLATION IN CRYPTOGENIC STROKE WITH AN INSERTABLE CARDIAC MONITOR COST EFFECTIVE?

Klaus Witte (United Kingdom) 

15

Q/A 


________________________________________________________________


STROKE PREVENTION AND MANAGEMENT IN CURRENT PRACTICE: OPTIMISING ORAL ANTICOAGULATION IN NVAF AND BEYOND

Wednesday, 11 May 2016
12:45 - 14:15, Hall D

Symposium is organised and supported by BMS & Pfizer Alliance

Chair: Antoni Dávalos (Spain)

12:45 - 12:50

WELCOME AND HOUSEKEEPING
Antoni Dávalos (Spain)

12:50 - 13:05

PRIMARY STROKE PREVENTION WITH NOACS​
Robert Hatala (Slovakia)

13:05 - 13:25

ACUTE STROKE MANAGEMENT – CONSIDERATIONS IN THE NOAC ERA
Antoni Dávalos (Spain)

5

INITIATING PREVENTION AFTER ACUTE STROKE IN NVAF AND BEYOND
George Ntaios (Greece)

13:45 - 14:05

SECONDARY STROKE PREVENTION IN NVAF – ARE THERE ALTERNATIVES TO NOACS?
Karl Georg Haeusler (Germany)

14:05 - 14:15

CLOSING REMARKS AND Q&A
​​All

__________________________________________________________________

ARE YOU READY FOR YOUR NEXT STROKE PATIENT? PRESENTING THE LATEST EVIDENCE, JUSTIFICATION AND TRATEGIES FOR ACUTE PHASE MANAGEMENT OF ISCHAEMIC STROKE

Wednesday, 11 May 2016
12:45 - 14:15, Hall E

by Boehringer Ingelheim

Chairs: Valeria Caso (Italy) and Kennedy Lees (United Kingdom)

12:45 - 13:05

TO LYSE OR NOT TO LYSE? THAT IS THE QUESTION!

Kennedy Lees (United Kingdom) 

13:05 - 13:20

IMPROVING AND EVALUATING PROCESSES OF CARE AND STROKE UNITS/NETWORKS

Atte Meretoja (Finland) 

13:2​0 - 13:35

ENCHANTED INSIGHTS INTO THROMBOLYSIS STRATEGY

Craig Anderson (Australia) 

13:35 - 13:50

ENDOVASCULAR THERAPY WITH THROMBOLYSIS: WHO CAN THE KNIGHT IN SHINING ARMOUR RESCUE?

Carlos Molina (Spain) 

13:5​​0 - 14:15

PANEL DISCUSSION

All 

__________________________________________________________________

BALANCING BENEFIT AND RISK WITH NON-VKA ORAL ANTICOAGULANTS IN AF-RELATED STROKE


Wednesday, 11 May 2016
12:45 - 14:15, Hall F

Symposium is organised and supported by Daiichi-Sankyo

Chairs: Ángel Chamorro (Spain) and Roland Veltkamp (United Kingdom)


12:45 - 12:50WELCOME AND INTRODUCTION
 Ángel Chamorro (Spain)

12:50 - 13:10RISK OF HAEMORRHAGIC STROKE WITH VKA VS NOACS
Heinrich Mattle (Switzerland)

13:10 - 13:20Q&A

13:20 - 13:40

BALANCING BENEFIT AND RISK IN PATIENT OUTCOMES: WHAT DOES THE ENGAGE AF-TIMI 48 TRIAL ADD?
 Freek Verheugt (The Netherlands) 

13:40 - 13:50Q&A

13:50 - 14:00INTERACTIVE CASE PRESENTATION
Florian Masuhr (Germany)

14:00 - 14:10

PANEL DISCUSSION OF INTERACTIVE CASE PRESENTATIONS
All 

14:10 - 14:15

CLOSING REMARKS
Roland Veltkamp (United Kingdom)​​ ​


Thursday, 12 May 2016


NOVEL STROKE PROPHYLAXIS STRATEGIES: WHEN SHOULD CARDIAC OCCLUSION THERAPIES BE CONSIDERED?​

Thursday, 12 May 2016
F

Symposium is organised and supported by St Jude Medical​

Chairs: Werner Hacke (Germany) and Per Wester (Sweden)

13:15 - 13:2​​0

INTRODUCTION AND OBJECTIVES
Werner Hacke (Germany)

13:20 - 13:29

THE HEART-AND-BRAIN CONNECTION - CURRENT KNOWLEDGE AND FUTURE CHALLENGES
Derk Krieger (Denmark)

13:29 - 13:32DISCUSSION AND AUDIENCE INTERACTION

13:32 - 13:42

HOW TO TREAT THE UNTREATABLE; WHAT ARE THE OPTIONS?
Dabit Arzamendi (Spain)

13:42 - 13:45DISCUSSION AND AUDIENCE INTERACTION

13:45 - 13:54

LONG TERM RESULTS OF THE RESPECT TRIAL: PFO CLOSURE VERSUS STANDARD MEDICAL CARE IN PATIENTS WITH PREVIOUS CRYPTOGENIC STROKE
Roman Huber (Germany)

13:54 - 13:57DISCUSSION AND AUDIENCE INTERACTION

13:57 - 14:07

A PROPENSITY SCORE MATCHED FOLLOW-UP STUDY - LEFT ATRIAL APPENDAGE OCCLUSION VERSUS STANDARD MEDICAL CARE IN PATIENTS WITH AF AND ICH
Per Wester (Sweden)

14:07 - 14:10DISCUSSION AND AUDIENCE INTERACTION

15

GE
Per Wester (Sweden)



Keep Me Updated